Kevin Chinn

Kevin Chinn began their career in 1991 as a Research Scientist II at Monsanto. In 2000, they moved to Pharmacia as a Principal Research Scientist, then to Pfizer in 2002 in the same role. In 2004, they began working at Cellular Bioengineering, Inc. as a Senior Research Scientist. In 2009, they joined Skai Ventures as Chief Scientific Officer of the E Canary Division, responsible for the Electronic Canary project and grant writing for the project and other uses of the E Canary algorithm. In 2013, they became Director of Pharmaceutical R&D at Trutag Technologies, where they developed methods for Trutag micro tag application onto tablets, as well as Director of Quality - R&D.

Kevin Chinn attended the University of California, Berkeley from 1973 to 1975 and obtained an A.B. in Physiology, General. Kevin then attended the University of Hawaii at Manoa from 1976 to 1981 and obtained a Doctor of Philosophy (Ph.D.) in Physiology, General. Afterward, they were a Postdoctoral Fellow at Brandeis University from 1981 to 1984. Finally, they were a Research Associate at Northwestern University from 1984 to 1986.